Andreas Gerber

Andreas Gerber has extensive work experience in the pharmaceutical industry, spanning several companies. Andreas is currently serving as the Chief Operating Officer at invIOs INNOVATIVE IMMUNO-ONCOLOGY since January 2022 and previously held the same position at APEIRON Biologics AG starting in February 2021. Prior to that, they worked at MSD from February 2019 to August 2020, serving as the Site Head & Executive Director Biologics and Vaccines Formulation. Before joining MSD, Gerber worked at Novartis where they held various roles, including Site Head Drug Substance Kundl, Biologics from July 2017 to December 2018, Process Unit Head Drug Substance Kundl, Biologics from April 2017 to June 2017, Process Unit Head Sandostatin & Signifor from November 2015 to March 2017, and Process Unit Head Sandostatin from August 2014 to October 2015. Andreas started their career at Bachem in 2003, where they held positions such as Head of Production from October 2013 to June 2014, Director Production from May 2009 to September 2013, and Teamleader Development from May 2003 to April 2009.

Andreas Gerber holds a Doctor of Philosophy - PhD degree in Organic Chemistry from the University of Basel. Additionally, they have completed an Executive MBA in General Management from the University of St.Gallen. However, no specific information regarding the start and end years for each degree is provided.